SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-197486"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-197486" > A 1-year pilot stud...

  • Hals, Ingrid K.Norwegian Univ Sci & Technol NTNU, Norway; Trondheim Reg & Univ Hosp, Norway; Nord Trondelag Hosp Trust, Norway (författare)

A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • WILEY,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-197486
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-197486URI
  • https://doi.org/10.1111/dom.15239DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:153532928URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|St Olavs hospital, Trondheim university hospital (Trondheim, Norway); Central Norway Regional Health Authority (Trondheim,Norway); Norwegian Diabetes Association(Oslo, Norway); Central Norway Regional Health Authority (Trondheim, Norway); Norwegian Diabetes Association (Oslo,Norway); St Olavs Hospital, Trondheim University Hospital(Trondheim, Norway)
  • Aims: To test, for the first time in latent autoimmune diabetes in adults (LADA), the effects of autoantigen-specific immunotherapy by intralymphatic administration of aluminium-formulated recombinant human glutamic acid decarboxylase 65 (GAD-alum); specifically, to test if this treatment is safe, to test whether it induces a strong immunological response akin to a similar protocol in type 1 diabetes and to look for associations with preserved beta-cell function. Materials and Methods: Three GAD-alum injections, 4 mu g each, were administered 1 month apart into an inguinal lymph node in 14 people with newly diagnosed LADA (age 30-62 years) presenting with high levels of antibodies against glutamic acid decarboxylase (GADA). Adverse effects, immunological variables and beta-cell function were monitored, with detailed measurements at 5 and 12 months from baseline. Results: Clinical adverse effects were minor and transient and measured laboratory variables were unaffected. All participants completed the study. Treatment raised levels of GADA, elicited strong effects on reactivity of peripheral blood mononuclear cells to GAD and raised cytokine/chemokine levels. Beta-cell function appeared stable preferentially in the seven participants carrying human leukocyte antigen (HLA) haplotypes DR3DQ2, as assessed by C-peptide glucagon tests (P < 0.05 vs. seven non-carriers). Conclusion: Intralymphatic treatment with GAD-alum in LADA is without clinical or other safety concerns over a 12-month period. As in a similar protocol used in type 1 diabetes, treatment exerts a strong immunological impact and is compatible with protection of beta-cell function preferentially in HLA-DR3DQ2 LADA patients. These findings pave the way for a randomized controlled trial in this important subgroup of LADA patients.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Balasuriya, ChandimaTrondheim Reg & Univ Hosp, Norway (författare)
  • Casas, RosauraLinköpings universitet,Avdelningen för barns och kvinnors hälsa,Medicinska fakulteten(Swepub:liu)rosca56 (författare)
  • Ludvigsson, JohnnyLinköpings universitet,Avdelningen för barns och kvinnors hälsa,Medicinska fakulteten,Region Östergötland, H.K.H. Kronprinsessan Victorias barn- och ungdomssjukhus(Swepub:liu)johlu29 (författare)
  • Bjorklund, AnneliKarolinska Inst, Sweden; Acad Specialist Ctr, Sweden (författare)
  • Grill, ValdemarNorwegian Univ Sci & Technol NTNU, Norway (författare)
  • Norwegian Univ Sci & Technol NTNU, Norway; Trondheim Reg & Univ Hosp, Norway; Nord Trondelag Hosp Trust, NorwayTrondheim Reg & Univ Hosp, Norway (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Diabetes, obesity and metabolism: WILEY25:11, s. 3400-34091462-89021463-1326

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy